MedTrace Logo

Guanfacine Extended-release for Adolescents With Cannabis Use

NCT05957848 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-07-31

No results posted yet for this study

Summary

A randomized controlled trial to assess the efficacy of extended-release guanfacine to reduce cannabis use frequency in young people with cannabis use disorder following a period of monitored abstinence.

Conditions

  • Cannabis Use Disorder

Interventions

DRUG

Guanfacine Extended Release Oral Tablet

Target dose 4 mg daily

BEHAVIORAL

Residential withdrawal

4-14 days in residential withdrawal treatment

BEHAVIORAL

Engagement with alcohol and other drug services

Ongoing engagement with a youth drug and alcohol service for counselling or other support for the duration of the study

DRUG

Placebo

Placebo capsule taken daily

Sponsors & Collaborators

  • Youth Support and Advocacy Service

    collaborator UNKNOWN

  • University of Melbourne

    collaborator OTHER

  • Orygen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-27
Primary Completion
2025-12-31
Completion
2026-06-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05957848 on ClinicalTrials.gov